Zymeworks, Inc. (ZYME)
28.77
+0.10
(+0.35%)
USD |
NASDAQ |
Aug 24, 16:00
29.70
+0.93
(+3.23%)
After-Hours: 06:56
Zymeworks Enterprise Value : 2.068B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.068B |
| August 21, 2026 | 2.061B |
| August 20, 2026 | 1.910B |
| August 19, 2026 | 1.956B |
| August 18, 2026 | 1.874B |
| August 17, 2026 | 1.819B |
| August 14, 2026 | 1.806B |
| August 13, 2026 | 1.852B |
| August 12, 2026 | 1.792B |
| August 11, 2026 | 1.748B |
| August 10, 2026 | 1.737B |
| August 07, 2026 | 1.692B |
| August 06, 2026 | 1.662B |
| August 05, 2026 | 1.689B |
| August 04, 2026 | 1.638B |
| August 03, 2026 | 1.567B |
| July 31, 2026 | 1.577B |
| July 30, 2026 | 1.632B |
| July 29, 2026 | 1.582B |
| July 28, 2026 | 1.625B |
| July 27, 2026 | 1.653B |
| July 24, 2026 | 1.643B |
| July 23, 2026 | 1.662B |
| July 22, 2026 | 1.679B |
| July 21, 2026 | 1.729B |
| Date | Value |
|---|---|
| July 20, 2026 | 1.708B |
| July 17, 2026 | 1.739B |
| July 16, 2026 | 1.739B |
| July 15, 2026 | 1.773B |
| July 14, 2026 | 1.773B |
| July 13, 2026 | 1.793B |
| July 10, 2026 | 1.860B |
| July 09, 2026 | 1.946B |
| July 08, 2026 | 1.916B |
| July 07, 2026 | 1.921B |
| July 06, 2026 | 1.821B |
| July 02, 2026 | 1.891B |
| July 01, 2026 | 1.849B |
| June 30, 2026 | 1.879B |
| June 29, 2026 | 1.674B |
| June 26, 2026 | 1.678B |
| June 25, 2026 | 1.650B |
| June 24, 2026 | 1.689B |
| June 23, 2026 | 1.658B |
| June 22, 2026 | 1.612B |
| June 18, 2026 | 1.603B |
| June 17, 2026 | 1.603B |
| June 16, 2026 | 1.555B |
| June 15, 2026 | 1.612B |
| June 12, 2026 | 1.584B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Theravance Biopharma, Inc. | 566.37M |
| BridgeBio Pharma, Inc. | 18.52B |
| Aprea Therapeutics, Inc. | -30.53M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.02M |
| Revenue (Quarterly) | 4.59M |
| Total Expenses (Quarterly) | 49.61M |
| EPS Diluted (Quarterly) | -0.6168 |
| Gross Profit Margin (Quarterly) | 57.43% |
| Profit Margin (Quarterly) | -980.8% |
| Earnings Yield | -7.00% |
| Normalized Earnings Yield | -6.992 |